A novel ErbB inhibitor called pyrotinib was well tolerated and showed promising activity in patients with metastatic HER2-positive breast cancer, according to results of a phase I trial. (Source: CancerNetwork)
from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2xujPo8
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,